CorMedix (CRMD) Non-Current Assets (2010 - 2025)
CorMedix (CRMD) reported Non-Current Assets of $459.1 million for Q4 2025, up 10649.03% on a YoY basis from N/an in Q4 2024, and down 6.56% sequentially from $491.3 million in Q3 2025.
CorMedix (CRMD) Non-Current Assets (2010 - 2025) Analysis & Trends
CorMedix (CRMD) has 15 years of Non-Current Assets data on file, last reported at $459.1 million in Q4 2025.
- For the quarter ending Q4 2025, Non-Current Assets rose 10649.03% year-over-year to $459.1 million; the trailing twelve-month figure through Dec 2025 stood at $959.7 million (up 5275.36% YoY), and the FY2025 full-year result was $459.1 million, up 10649.03% from the prior year.
- Non-Current Assets eased to $459.1 million in Q4 2025, from $491.3 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $491.3 million in Q3 2025 to a low of $1.2 million in Q2 2021.
- A 5-year average of $50.2 million and a median of $2.5 million in 2021 frame the typical range for Non-Current Assets.
- Across the five-year window, Non-Current Assets dropped 1.9% in 2023 and jumped 10986.07% in 2025, its largest moves.
- Tracing CRMD's Non-Current Assets over 5 years: stood at $2.5 million in 2021, then climbed by 0.42% to $2.5 million in 2022, then gained by 4.92% to $2.6 million in 2023, then jumped by 63.67% to $4.3 million in 2024, then jumped by 10649.03% to $459.1 million in 2025.
- Business Quant data shows CRMD's Non-Current Assets at $459.1 million in Q4 2025, $491.3 million in Q3 2025, and $4.5 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 5.83 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.95 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 3.95 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.96 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 285.82 Mn |
| 10 | CorMedix | 546.82 Mn | 391.62 Mn | 107.31 Mn | 459.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 459.09 Mn |
| Sep 30, 2025 | 491.33 Mn |
| Jun 30, 2025 | 4.54 Mn |
| Mar 31, 2025 | 4.72 Mn |
| Dec 31, 2024 | 4.27 Mn |
| Sep 30, 2024 | 4.43 Mn |
| Jun 30, 2024 | 4.54 Mn |
| Mar 31, 2024 | 4.61 Mn |
| Dec 31, 2023 | 2.61 Mn |
| Sep 30, 2023 | 2.37 Mn |
| Jun 30, 2023 | 2.41 Mn |
| Mar 31, 2023 | 2.45 Mn |
| Dec 31, 2022 | 2.49 Mn |
| Sep 30, 2022 | 2.41 Mn |
| Jun 30, 2022 | 2.39 Mn |
| Mar 31, 2022 | 2.43 Mn |
| Dec 31, 2021 | 2.48 Mn |
| Sep 30, 2021 | 2.40 Mn |
| Jun 30, 2021 | 1.17 Mn |
| Mar 31, 2021 | 1.20 Mn |